Biovail Q210 Financial Results Reflects Its High Exposure To US Market Forces

Biovail posted pharmaceutical sales growth of 23% for Q210, with sales increasing to US$231.2mn compared with US$187.7mn in the same period in 2009. Second-quarter Generally Accepted Accounting Principles (GAAP)'s net income rose 41% to US$34.0mn from the US$24.1mn reported in Q209. Sales for the six months ended June 30 2010 was US$458.4mn, a 25% increase on the US$366.9mn reported for H109.

To read the full article, please choose one of the following options: